MAPT and Alzheimer disease: Treatment of 3xTg-AD mice with AF710B (10 μg/kg delivered by intraperitoneal injections daily for 2 months) reduced levels of BACE1, Aβ1–42, plaques, p25/CDK5, GSK-3β activity, Tau phosphorylation and memory deficits in the Morris water-maze (Fisher et al., 2016).